Nuclear Medicine: Core Physics, Radiopharmaceuticals, and Diagnostic Reasoning
What the exam expects
Build your review around four pillars: (1) radionuclide production and decay, (2) detection and instrumentation, (3) biodistribution and dosimetry, and (4) organ-system pattern recognition. Understand that most clinically used isotopes are generator-produced (Mo-99/Tc-99m) or cyclotron-produced (F-18, Ga-68, I-123), and that photon energy, physical half-life, and emission type dictate which detector and collimator are appropriate. Know that Tc-99m emits a 140 keV gamma ray with a 6-hour half-life, while positron emitters are detected by coincidence of paired 511 keV annihilation photons.
Concepts to master
Differentiate planar scintigraphy, SPECT, and PET in terms of spatial resolution, attenuation correction, and typical indications. Understand collimator choice (low-energy high-resolution vs. medium-energy) and how septal penetration degrades images. Know radiopharmaceutical localization mechanisms: active transport (iodine into thyroid), capillary blockade (macroaggregated albumin in lung), chemisorption (Tc-99m MDP to bone), and receptor/transporter targeting (sestamibi mitochondrial uptake).
Traps
Questions commonly test whether a finding is physiologic or pathologic: gastric/bowel uptake of pertechnetate, renal excretion on bone scans, myocardial uptake of MDP, and thymic rebound are benign. Another trap is confusing the radiopharmaceutical with the imaging modality, or assuming a positive study is diagnostic without correlating clinical context. Watch for half-life arithmetic errors and for questions that ask about the mechanism rather than the finding.
Rule of thumb
After roughly 5 physical half-lives, ~97% of activity has decayed; use this to decide when residual activity no longer limits a repeat study. Worked example: a Tc-99m dose of 20 mCi remaining in a syringe after 12 hours (two half-lives) retains about 5 mCi-so re-dosing requires accounting for both the residual and the patient's prior exposure.